NKTR — NEKTAR THERAPEUTICS
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 906709 ·
Last close
$73.69
Market Cap
$2.52B
52W High
$77.23
52W Low
$54.13
ADV30
671,814
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 10,861,000 | — | -38,258,000 | -44,904,000 | 763,271,000 | 149,578,000 | 187,055,000 |
| Dec 2025 | 21,807,000 | 21,807,000 | -19,090,000 | -36,079,000 | 280,406,000 | 15,116,000 | 190,574,000 |
| Sep 2025 | 11,790,000 | 11,790,000 | -31,532,000 | -35,522,000 | 301,347,000 | 41,032,000 | 216,261,000 |
| Jun 2025 | 11,175,000 | 11,175,000 | -35,783,000 | -41,593,000 | 207,534,000 | 42,988,000 | 231,745,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-203,756,000
Investing CF
$-395,675,000
Financing CF
$710,108,000
CapEx
$-187,000
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-8.42
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-3,805,190,000
Inventory
$0
Receivables
$3,600,000
ST Investments
$419,026,000
EBIT TTM
$-123,056,000
Pretax Income TTM
$-152,208,000
Interest Exp TTM
$29,152,000
Analysts
9
Yahoo Snapshot (yfinance, live)
Total Revenue
$54,589,000
EBITDA
$-129,950,000
Free Cash Flow
$-134,766,368
Enterprise Value
$1,967,590,272
Total Cash
$684,340,992
Total Debt
$135,934,000
Shares Out
34,142,994
Trailing EPS
$-6.09
Book Value
$26.46
ROE
-35.8%
ROA
-12.5%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 55,232,000 | -130,771,000 | -164,076,000 | 280,406,000 | 190,574,000 | — | -208,511,000 |
| Dec 2024 | 98,427,000 | -129,918,000 | -118,961,000 | 303,850,000 | 243,113,000 | — | -175,709,000 |
| Dec 2023 | 90,122,000 | -135,225,000 | -276,056,000 | 398,033,000 | 267,046,000 | — | -192,606,000 |
| Dec 2022 | 92,055,000 | -240,236,000 | -368,198,000 | 710,600,000 | 343,962,000 | — | -304,007,000 |
TTM Snapshot
Revenues TTM
$105,757,000
NetIncome TTM
$-495,945,000
OpCashFlow TTM
$0
Assets (Latest)
$710,600,000
Forward EPS
$-10.84
Max Pain — expiry 2026-09-18
max pain strike: $50.00 · spot: $73.69 · call oi: 7,036 · put oi: 0
Expected Move to 2026-09-18:
±$10.39
(14.10%) —
implied range
$63.30 –
$84.08
· ATM straddle on $75.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| BHC | Bausch Health Companies Inc. | $2.50B | $6.68 | — |
| RARE | Ultragenyx Pharmaceutical Inc. | $2.54B | $25.72 | — |
| PGEN | PRECIGEN, INC. | $2.56B | $7.17 | — |
| PBH | Prestige Consumer Healthcare Inc. | $2.46B | $52.02 | — |
| TRVI | Trevi Therapeutics, Inc. | $2.58B | $18.08 | — |
News headlines (Yahoo Finance, 1h cache)
Nektar (NKTR) Q2 2026 Earnings Call Transcript
2026-08-20 23:34 · Yahoo
Nektar Therapeutics (NKTR) Could Be 52% Undervalued After Q2 Earnings Surprise
2026-08-15 02:09 · Yahoo
Nektar Therapeutics (NKTR) Stock Looks Stretched Despite New Phase 3 Trial Launch
2026-08-14 15:12 · Yahoo
Nektar Therapeutics (NKTR) (Q2 2026) Earnings Call Highlights: Respeg Phase 3 Momentum and ...
2026-08-14 05:01 · Yahoo
Nektar Therapeutics Announces Second Quarter 2026 Financial Results
2026-08-13 20:15 · Yahoo
Nektar Therapeutics to Announce Financial Results for the Second Quarter on Thursday, August 13, 2026, After Close of U.S.-Based Financial Markets
2026-07-28 22:00 · Yahoo
Nektar Therapeutics Announces Start of Phase 3 ZENITH AD Program Evaluating Novel Regulatory T-Cell Biologic Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis
2026-07-21 11:00 · Yahoo
NKTR Stock Clocks Best Day In Over 2 Months As Investors Await Upcoming Clinical Data In Eczema
2026-07-03 00:41 · Yahoo
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-06-26 20:30 · Yahoo
What a $1.2 Million Insider Sale Means for Nektar With Shares Up 160% This Past Year
2026-06-24 19:59 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.